FATE THERAPEUTICS INC
FATE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FATE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FATE
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies, with a focus on programmed cell therapies for cancer.
Key risk: Clinical-stage with no approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$291.2M
Cash Runway
19.1 moLead Asset
FT522 (Phase 1)
Next Catalyst
Phase3_Topline · Jan 1, 2027Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 42 clinical trials · 4 catalysts for FATE THERAPEUTICS INC.
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies, with a focus on programmed cell therapies for cancer.
- Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to off-the-shelf cellular immunotherapies [sec_mda · as of 2026-02-26].
- As of 2026-06-30, the company reported cash & equivalents of $32.4M, total revenue of $2.1M, and a net loss of $30.2M [sec].
- The company's pipeline includes multiple Phase 3 trials with topline data expected between 2027 and 2033 [upcoming catalysts].
- Fate Therapeutics has an accumulated deficit and expects to continue incurring losses, with capital requirements dependent on clinical trial progress and manufacturing costs [sec_mda · as of 2026-08-13].
What works
- Fate Therapeutics is advancing a pipeline of off-the-shelf cellular immunotherapies, which could offer advantages over personalized cell therapies in terms of scalability and accessibility [sec_mda · as of 2026-02-26].
- The company has multiple Phase 3 trials underway, with several topline data readouts expected in the coming years, indicating a maturing pipeline [upcoming catalysts].
What to weigh
- Fate Therapeutics is a clinical-stage company with no approved products and has incurred significant net losses, including a net loss of $30.2M for the quarter ended June 30, 2026 [sec].
- The company's cash position of $32.4M as of June 30, 2026, may be insufficient to fund all planned operations, and it may need to raise additional capital, which could dilute existing shareholders [sec_mda · as of 2026-08-13].
- The company faces risks related to clinical trial delays, manufacturing costs, and regulatory uncertainties that could impact its ability to bring products to market [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on off-the-shelf cellular immunotherapies.
“We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the shelf cellular immunotherapies to patients.”
SEC MD&A · February 26, 2026
Capital requirements depend on clinical trial progress and manufacturing costs.
“the initiation, timing, progress, size, duration, costs and results of our clinical trials and preclinical studies for our product candidates, including the timing and costs of manufacturing activities to support such clinical trials and preclinical studies”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2027-01-01 · Phase3_Topline — Phase 3 Topline: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or — Topline data from this Phase 3 trial will provide key efficacy and safety results for the combination regimen.
- 2027-12-15 · Phase3_Topline — Phase 3 Topline: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bev — This topline readout will compare multiple treatment arms, potentially informing standard of care in this indication.
- 2029-11-30 · Phase3_Topline · pembrolizumab — Phase 3 Topline: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic H — Results will assess the benefit of adding cetuximab to pembrolizumab in recurrent or metastatic head and neck cancer.
- 2033-12-31 · Phase3_Topline · camrelizumab — Phase 3 Topline: Randomized Controlled Trial of Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy f — This late-stage readout will evaluate camrelizumab combinations in a specific cancer setting.
Risks & what to watch (4)›
Key risks
- Clinical-stage with no approved products — Fate Therapeutics has no approved products and relies on successful clinical development and regulatory approval [sec_mda · as of 2026-02-26].
- Limited cash runway — Cash of $32.4M as of June 30, 2026, may not be sufficient to fund all planned operations, requiring additional financing [sec].
- Dependence on clinical trial outcomes — The company's future depends on the success and timing of its clinical trials, which are subject to delays and failures [sec_mda · as of 2026-08-13].
- Manufacturing and scalability risks — Manufacturing costs and scalability of off-the-shelf cell therapies are key uncertainties [sec_mda · as of 2026-08-13].
What to watch
- Phase 3 topline data for the randomized Phase II/III trial of adjuvant radiation therapy with cisplatin, docetaxel-cetuximab, or other regimens, expected in January 2027 [upcoming catalysts].
- Phase 3 topline data for the trial of chemotherapy + cetuximab vs chemotherapy + bevacizumab vs atezolizumab + bevacizumab, expected in December 2027 [upcoming catalysts].
- Phase 3 topline data for the pembrolizumab trial in recurrent or metastatic head and neck cancer, expected in November 2029 [upcoming catalysts].
- Phase 3 topline data for the camrelizumab combination trial, expected in December 2033 [upcoming catalysts].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run FATE THERAPEUTICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FATE THERAPEUTICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
19.1 months
D/E 0.70 · 0% dilution
Lead: Phase 2
5 candidates
4 upcoming, next in ~124d
0 buys · 4 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
154
Total value held
$73.3M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 10,068,614 | $12.1M |
| vanguard capital management llc | 8,384,126 | $10.1M |
| vanguard portfolio management llc | 4,134,585 | $5.0M |
| two sigma investments, lp | 3,466,786 | $4.2M |
| johnson & johnson | 3,379,064 | $4.1M |
| aqr capital management llc | 3,001,521 | $3.6M |
| renaissance technologies llc | 2,974,683 | $3.6M |
| geode capital management, llc | 2,590,429 | $3.1M |
| state street corp | 2,263,173 | $2.7M |
| ubs group ag | 1,821,715 | $2.2M |
Showing top 10 of 154 institutional holders of FATE THERAPEUTICS INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 10.0%
- Days to cover
- 8.9
- Shares short
- 10,255,224
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FATE short interestGovernance
Frequently asked questions
What is the AI investment thesis for FATE THERAPEUTICS INC?
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies, with a focus on programmed cell therapies for cancer.
What is FATE THERAPEUTICS INC's lead drug candidate?
FATE THERAPEUTICS INC's most advanced tracked candidate is FT522 (Phase 1) for Relapsed/Refractory B-Cell Lymphoma.
What is FATE THERAPEUTICS INC's next catalyst?
FATE THERAPEUTICS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or " — expected January 1, 2027.
Who is the CEO of FATE THERAPEUTICS INC?
Dr. Bahram Valamehr M.B.A., Ph.D. is the chief executive officer of FATE THERAPEUTICS INC (FATE).
Where is FATE THERAPEUTICS INC headquartered?
FATE THERAPEUTICS INC (FATE) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.